Clinical Trial Update: Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

View source ↗

Summary

In high-risk patients, switching from higher doses of other statins to Crestor increased the proportion reaching the new LDL-C target.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Hypercholesterolemia | Status: COMPLETED